India looks to attract more trials with new compensation formula for participants

India looks to attract more trials with new compensation formula

As part of an effort to provide more certainty, India’s CDSCO (Central Drugs Standards Control Organization) has offered up a new compensation formula for trial participants who are killed or injured during a trial.

The draft formula -- which replaces an earlier iteration of the formula that was contested for allowing compensation due to product failures – is based on the patient’s age, risk factor for a disease and a base amount of 8 lakhs, or about $13,000. For patients whose expected mortality is 90% or more within 30 days, a fixed amount of about $3000 will be provided to patients.

Despite the changes, some industry experts don’t believe that industry will push for more clinical trials in the subcontinent any time soon.

John Lewis, senior VP of ACRO (Association of Clinical Research Organizations) told us, "It is doubtful there will be a major return of clinical trials to India until the political situation is settled and a new government has provided clear signs that research is again welcome in the country.”

He added: “Remember that, at its peak, India accounted for only about 3% of global clinical trial activity. So, while we remain optimistic about the future the current situation is still very unsettled."

In April, a committee under the Department of Health and Family Welfare considered different compensation formulas for serious adverse events that result in permanent disability, birth defect, chronic life-threatening disease or reversible adverse event. Most of those formulae are based on the number of days a worker is kept from his work, as well as the minimum wage per day of an unskilled worker.

Experts have until May 16th to comment on the new compensation formulae.

The changes come as the Indian Supreme Court called for drastic changes to the conduct of clinical trials following allegations of lax approvals and a higher-than-usual death rate. The government has since set up committees to take a closer look at how trials are approved and how to be fairer to trial participants. 

Related News

CDSCO promises "written confirmation" reviews in 30 days

Doubts over CDSCO claim it can assess an API supplier in 30 days

CDSCO issues raft of new trial regulations

CDSCO issues raft of new trial regulations

India to reward folk who report fake drugs

India's CDSCO to pay people who report fake drugs

Through May 2014, 76 trials have been approved, which is more than triple the number of trials approved through May 2013

Indian clinical trial approvals see early spike in 2014

More new rules for trial sponsors and CROs in India

More new rules for trial sponsors and CROs in India

India aims to make new clinical trial rules permanent with draft bill

India aims to make new clinical trial rules permanent with draft bill

Inside India: A voyage into pharma manufacturing, trial policies

Inside India: A voyage into the subcontinent's pharma manufacturing, clinical trial policies

Strides Arcolab wins FDA approval for India facility

Strides Arcolab wins FDA approval for India facility

Indian regulator revokes manufacturing suspension at Wockhardt plant

Indian state regulator revokes manufacturing suspension at Wockhardt plant

Related Products

See more related products